Clinical and translational gastroenterology · 2026
Glucosyl Hesperidin Benefits in Primary Biliary Cholangitis: A Multicenter, Open-Label, Randomized Controlled Study.
СтатьяРандомизированное исследованиеМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Moriya Kei, Asada Kiyoshi, Ozu Naoki, Suzuki Shota, Fujinaga Yukihisa, Enomoto Masahide, Tsuji Yuki, Komeda Yusuke, Hanatani Junichi, Kaya Daisuke, Matsuo Yuya, Nagamatsu Shinsaku, Matsuo Hideki, Uejima Masakazu, Yamazaki Masaharu, Yoshiji Hitoshi
Аннотация
INTRODUCTION: Primary biliary cholangitis (PBC) has steadily increased in incidence, but its causes remain to be completely elucidated. Moreover, the potential for disease progression is not uncommon, especially when normalization of hepatobiliary enzyme levels is difficult, making the emergence of new treatments highly anticipated. We clarified the therapeutic effects of glucosyl hesperidin (G-Hes), which activates the antioxidant NRF2/KEAP1 pathway, on improving PBC pathophysiology.
METHODS: This randomized controlled trial evaluated changes in serum levels of hepatobiliary enzymes, lipids, and heme oxygenase 1, which is an NRF2/KEAP1 pathway target gene protein, after G-Hes administration (500 or 1,000 mg/d) for 24 weeks in 71 patients on maintenance therapy for PBC.
RESULTS: Gamma glutamyl transferase at week 24, the primary end point of this study, decreased significantly by 6.2% only in the high dose group. Among the secondary end points, alkaline phosphatase increased plausibly because of G-Hes-induced bone metabolism enhancement and bilirubin decreased, both reaching significance only in the standard dose group. There were no significant changes in transaminases in either group. On subgroup analyses of patients with abnormal baseline biochemical levels, significant decrease in gamma glutamyl transferase at week 24 (6.4%) still remained only in the high-dose group. On the other hand, there was no significant change in alkaline phosphatase at any time point in both groups. The blood protein concentration of heme oxygenase 1 increased by 4.8% at week 24, although not significant. There were no G-Hes-related adverse events.
DISCUSSION: Inclusion of G-Hes to existing treatment safely provided additional therapeutic effects in patients with PBC.
METHODS: This randomized controlled trial evaluated changes in serum levels of hepatobiliary enzymes, lipids, and heme oxygenase 1, which is an NRF2/KEAP1 pathway target gene protein, after G-Hes administration (500 or 1,000 mg/d) for 24 weeks in 71 patients on maintenance therapy for PBC.
RESULTS: Gamma glutamyl transferase at week 24, the primary end point of this study, decreased significantly by 6.2% only in the high dose group. Among the secondary end points, alkaline phosphatase increased plausibly because of G-Hes-induced bone metabolism enhancement and bilirubin decreased, both reaching significance only in the standard dose group. There were no significant changes in transaminases in either group. On subgroup analyses of patients with abnormal baseline biochemical levels, significant decrease in gamma glutamyl transferase at week 24 (6.4%) still remained only in the high-dose group. On the other hand, there was no significant change in alkaline phosphatase at any time point in both groups. The blood protein concentration of heme oxygenase 1 increased by 4.8% at week 24, although not significant. There were no G-Hes-related adverse events.
DISCUSSION: Inclusion of G-Hes to existing treatment safely provided additional therapeutic effects in patients with PBC.